medscape.com
Cure8 news brief
Why This Matters
Detecting neoplasia early is a central goal of IBD surveillance; this study suggests virtual chromoendoscopy may find more lesions than dye or white light in real-world practice, which could influence how surveillance is done and what patients are offered during colonoscopy.
Who Should Pay Attention
Clinicians performing IBD surveillance, endoscopy unit leads, researchers in endoscopic imaging, and patients with long-standing IBD or PSC undergoing surveillance.
Study Snapshot
Story typeResearch news
Evidence typeClinical study
Source depthFull source text
What To Know
This Medscape report summarizes a multicenter retrospective cohort presented at ECCO 2025 comparing endoscopic imaging modalities for IBD surveillance.
The study reviewed 2673 surveillance colonoscopies (dye chromoendoscopy, virtual chromoendoscopy, and high-definition white light) performed across five UK centers from 2019–2023 and found the highest neoplasia detection rate with virtual chromoendoscopy (19%) versus dye chromoendoscopy (12%) and white light endoscopy (9%).
The authors and session discussants noted substantial real-world variability between centers in surveillance practice, differences in withdrawal times, and heterogeneity in patient mixes; the report stresses these as limitations. Ongoing analyses will look at neoplasia types, endoscopist experience, and repeat procedures.
This is a conference-associated observational study reported by Medscape; it is not a guideline change or randomized trial result. The article quotes presenters and commentators and notes potential conflicts of interest.
Keep In Mind
Findings come from a retrospective multicenter cohort presented at a conference; there are noted limitations including variable withdrawal times and heterogeneous patient populations between centers. This is not a guideline change by itself.
Source Details
Review the original publication for the complete reporting, methods, and context.
Publicationmedscape.com
Indexed viaBing News
Source typeResearch news
PublishedFeb 25, 2025, 3:58 AM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
IBD colorectal guidelines
People with IBD have a higher lifetime risk of colorectal cancer; updated UK guidelines give clinicians and patients evidence-based recommendations on when and how to do surveillance colonoscopy to detect precancerous...
Biomerica Achieves IVDR Certification in the European Union for Food Intolerance Tests Targeting Crohn’s Disease and Ulcerative Colitis
A new CE-marked food-intolerance diagnostic could give people with Crohn’s or UC a non-invasive tool to explore dietary triggers alongside clinical care. Regulatory certification means the products met EU safety and...
A drop of blood distinguishes Crohn's disease from ulcerative colitis...Laying the foundation for customized treatment of inflammatory bowel disease
Based on the title and source metadata, this appears to be a biomarker study related to Crohn's disease, Ulcerative colitis, and Inflammatory bowel disease. The original article is from msn.com.